Contact Us
Drug Search Results
More Filters [+]

LY-4170156

Alternative Names: LY-4170156, LY 4170156, LY4170156
Latest Update: 2024-08-09
Latest Update Note: Clinical Trial Update

Product Description

A putative antibody-drug conjugate (ADC) targeting folate receptor alpha (FRa). (Sourced from: https://ckb.jax.org/therapy/show/16931)

Mechanisms of Action: FOSL1 Inhibitor

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LY-4170156

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Breast Cancer|Cervical Cancer|Colorectal Cancer|Endometrial Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
jRCT2031240270

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

2027-08-31

LOXO-FRA-24001

P1

Recruiting

Non-Small-Cell Lung Cancer|Breast Cancer|Endometrial Cancer|Cervical Cancer|Colorectal Cancer|Pancreatic Cancer|Ovarian Cancer

2027-02-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions